Sak Katrin, Everaus Hele
Department of Hematology and Oncology, University of Tartu, Tartu, Estonia.
Curr Genomics. 2017 Feb;18(1):3-26. doi: 10.2174/1389202917666160803165447.
Despite the extensive work on pathological mechanisms and some recent advances in the treatment of different hematological malignancies, leukemia continues to present a significant challenge being frequently considered as incurable disease. Therefore, the development of novel therapeutic agents with high efficacy and low toxicity is urgently needed to improve the overall survival rate of patients. In this comprehensive review article, the current knowledge about the anticancer activities of flavonoids as plant secondary polyphenolic metabolites in the most commonly used human established leukemia cell lines (HL-60, NB4, KG1a, U937, THP-1, K562, Jurkat, CCRF- CEM, MOLT-3, and MOLT-4) is compiled, revealing clear anti-proliferative, pro-apoptotic, cell cycle arresting, and differentiation inducing effects for certain compounds. Considering the low toxicity of these substances in normal blood cells, the presented data show a great potential of flavonoids to be developed into novel anti-leukemia agents applicable also in the malignant cells resistant to the current conventional chemotherapeutic drugs.
尽管在病理机制方面开展了大量工作，且近期不同血液系统恶性肿瘤的治疗也取得了一些进展，但白血病仍然是一个重大挑战，常被视为不治之症。因此，迫切需要开发高效低毒的新型治疗药物，以提高患者的总体生存率。在这篇全面的综述文章中，汇总了目前关于黄酮类化合物作为植物次生多酚代谢产物在最常用的人类白血病细胞系（HL-60、NB4、KG1a、U937、THP-1、K562、Jurkat、CCRF-CEM、MOLT-3和MOLT-4）中的抗癌活性的知识，揭示了某些化合物具有明显的抗增殖、促凋亡、细胞周期阻滞和诱导分化作用。鉴于这些物质对正常血细胞的低毒性，所呈现的数据表明黄酮类化合物具有巨大潜力，可开发成新型抗白血病药物，也适用于对当前传统化疗药物耐药的恶性细胞。
